Kinarus Therapeutics Holding AG announced the signing of a strategic convertible loan agreement for a CHF 1.5 million on May 10, 2023. The transaction will include participation from new investor, ChaoDian (Hangzhou) Investment Management Co., Ltd. Under the terms of the loan agreement, the subordinated loan have a fixed term of three years without any interest. During the term of the agreement, the outstanding loan amount can be converted at any time into shares with a nominal value of CHF 0.01 at a fixed conversion price of CHF 0.01 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15 CHF | -6.99% | -6.99% | +737.05% |
- Stock Market
- Equities
- CURE Stock
- News Kinarus Therapeutics Holding AG
- Kinarus Therapeutics Holding AG announced that it expects to receive CHF 1.5 million in funding from ChaoDian Investment Management Co., Ltd.